Combination of anastrozole with fulvestrant in the intratumoral aromatase xenograft model

Cancer Research

Volumn 68, Issue 9, 2008, Pages 3516-3522

  Macedo, Luciana F ^a   Sabnis, Gauri J ^a   Goloubeva, Olga G ^b   Brodie, Angela ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; DRUG DERIVATIVE; ESTRADIOL; GROWTH FACTOR RECEPTOR; NITRILE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; UTERUS WEIGHT; XENOGRAFT; ANIMAL; BREAST TUMOR; CELL CULTURE; CELL PROLIFERATION; DRUG SCREENING; ENZYMOLOGY; METABOLISM; NUDE MOUSE; ORGAN SIZE; OVARIECTOMY; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; UTERUS;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; ESTRADIOL; FEMALE; HUMANS; MICE; MICE, NUDE; NITRILES; ORGAN SIZE; OVARIECTOMY; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; TRIAZOLES; TUMOR BURDEN; TUMOR CELLS, CULTURED; UTERUS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 44849089392     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6807     Document Type: Article

References (48)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2007;57:43-66.
2. Hemsell DL, Gordon J, Breuner PF, Siiteri PK. Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocr Metab 1974;38:476-9.
3. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225-30.
4. Tekmal RR, Ramachandra N, Gubba S, et al. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res 1996;56:3180-5.
5. Blankenstein MA, van de Ven J, de Jong PC, Thijssen JHH. Intratumoral levels of estrogens in breast cancer. Xth International Congress on Hormonal Steroids, Quebec City, Canada, 1998.
6. Lipton A, Santen RJ, Santen SJ, et al. Aromatase activity in primary and metastatic human breast cancer. Cancer 1987;59:779-83.
7. Miller WR, O'Neill JS. The significance of steroid metabolism in human cancer. J Steroid Biochem Mol Biol 1990;37:317-25.
8. Lu Q, Nakmura J, Savinov A, et al. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 1996;137:3061-8.
9. Sasano H, Ozaki M. Aromatase Expression and its localization in human breast cancer. J Steroid Biochem Molec Biol 1997;61:293-8.
10. de Jong PC, Blankenstein MA, Nortier JW, et al. The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease. J Steroid Biochem Mol Biol 2003;87:149-55.
11. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
12. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-95.
13. Howell A, Osborne CK, Morris C, Wakeling AE. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 2000;89:817-25.
14. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403.
15. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229-38.
16. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003;39:1684-9.
17. Bonneterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the TARGET (Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability) study. J Clin Oncol 2000;18:3748-57.
18. Johnston SR, Dowett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003;3:821-31.
19. Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM. Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res 2005;65:5380-9.
20. Sabnis GJ, Jelovac D, Long BJ, Schayowitz A, Belosay A, Brodie AMH. Mammalian target of rapamycin (mTOR) as a target in human breast cancer cells that have acquired resistance to aromatase inhibitor letrozole. AACR Meeting Abstracts 2006.
21. Hay N. The AKT-mTor tango and its relevance to cancer. Cancer Cell 2005;8:179-83.
22. Santen RJ, Song RX, Zhang Z, et al. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer 2005;12:S61-73.
23. Yue W, Wang J, Savinov A, Brodie A. The effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res 1995;55:3073-7.
24. Van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schroder FH. Adrenal glands of mouse and rat do not synthesis androgens. Life Sci 1992;50:857-61.
25. Rebar RW, Morandini IC, Erickson GF, Petze JE. The hormonal basis of reproductive defects in athymic mice: diminished gonadotropin concentrations in prepubertal females. Endocrinology 1981;108:120-6.
26. Zhou D, Pompom D, Chen S. Stable expression of human aromatase complementary DNA in mammalian cells: a useful system for aromatase inhibitor screening. Cancer Res 1990;50:6949-54.
27. Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O. Therapeutic observations in MCF-7 aromatase xenografts. Clin Cancer Res 2005;11:884-8s.
28. Perey L, Paridaens R, Hawle H, et al. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 2007;18:64-9.
29. Ingle JN, Suman VJ, Rowland KM, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006;24:1052-6.
30. Macedo L, Sabnis G, Moreira TH, Zhu Y, Goloubeva O, Brodie A. Effects of combining the aromatase inhibitor anastrozole with fulvestrant in the intratumoral aromatase mode. AACR Meeting Abstracts 2007.
31. Brunner N, Frandsen TL, Holst-Hansen C, et al. MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res 1993;53:3229-32.
32. Long B, Tilghman SL, Yue W, Thiantanawat A, Grigoryev DN, Brodie AMH. The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity. J Steroid Biochem Mol Biol 1998;67:293-304.
33. Baum M, Budzar AU, Cuzick J, et al. The ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002;359:2131-9.
34. Nicholson RI, Gee JM. Estrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer. Br J Cancer 2000;82:501-13.
35. Chen S, Masri S, Wang X, Phung S, Yuan YC, Wu X. What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol 2006;102:232-40.
36. Leary A, Dowsett M. Combination therapy with aromatase inhibitors: the next era of breast cancer treatment? Br J Cancer 2006;95:661-6.
37. Wang JP, Conaway M, Masamura S, Li S, Santen RJ. Activation of the MAPK pathway enhances sensitivity of MCF-7 breast cancer cells to the mitogenic effect of estradiol. Endocrinology 2002;143:3221-9.
38. Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AMH. Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model. Cancer Res 2005;65:5439-44.
39. Larsen SS, Madsen MW, Jensen BL, Lykkesfeldt AE. Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness. Int J Cancer 1997;72:1129-36.
40. Robertson JF. Fulvestrant (Faslodex) how to make a good drug better. Oncologist 2007;12:774-84.
41. Sabnis GJ, Jelovac D, Long B, Brodie A. The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 2005;65:3903-10.
42. Pietras RJ. Biologic basis of sequential and combination therapies for hormone-responsive breast cancer. Oncologist 2006;11:704-17.
43. Sabnis G, Jelovac D, Long B, Brodie A. Inhibition of growth factor receptor and ERa pathways improve sensitivity to treatment of long term estrogen deprived human breast cancer cells. AACR Meeting Abstracts 2005.
44. Kinoshita Y, Chen S. Induction of aromatase (CYP19) expression in breast cancer cells through a nongenomic action of estrogen receptor a. Cancer Res 2003;63:3546-55.
45. Osipo C, Gajdos C, Liu H, Chen B, Jordan VC. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 2003;95:1597-608.
46. Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) α, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003;278:30458-68.
47. Johnston SR, Martin LA, Head J, Smith I, Dowsett M. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 2005;95:173-81.
48. Macedo LF, Sabnis G, Brodie A. Preclinical modeling of endocrine response and resistance: focus on aromatase inhibitors. Cancer 2008;112:679-88.